Tarsus Pharmaceuticals, Inc. TARS Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Total revenues by Product | ||||
| License fees and collaboration revenue | $0-100% | $2.89M+6.5% | $2.72M-89.5% | |
| Product sales, net | $451.36M+151% | $180.06M+1,122% | $14.73M— | |
| Maximum milestone payments by Product | ||||
| Clinical Milestones | $16M0.0% | $16M0.0% | $16M-3.0% | |
| Commercial and Sales Milestones | $308M0.0% | $308M-1.3% | $312M— | |
| Milestone payments to be achieved by Product | ||||
| Development and Regulatory Milestone | $270M0.0% | $270M+0.9% | $267.5M— | |
| Upon Execution of the Novation Agreement | $10M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tarsus Pharmaceuticals, Inc. break its business down?
- Tarsus Pharmaceuticals, Inc. (TARS) reports total revenues by product across 2 parts — License fees and collaboration revenue and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does Tarsus Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tarsus Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
